CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
Capital Com Australia Pty Ltd Australia (受监管于 ASIC) Capital Com UK Limited 受监管于 Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (受监管于 CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (受监管于 NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (受监管于 FSA) Capital Com Online Investments Ltd (受监管于 SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
您也可以联系我们： 致电 +44 2030978888 support@capital.com

交易 Ionis Pharmaceuticals, Inc. - IONS CFD

33.67
0.71%
0.24
最低: 33.6
最高: 34.22
Market Trading Hours* (UTC) Opens on Tuesday at 13:30

Mon - Fri: 13:30 - 20:00

  • 概括
  • 历史数据
  • 活动
  • 收入报表
  • 资产负债表
  • 现金流
  • 所有权
交易条件
价差 0.24
多头隔夜费

Long position overnight fee

Margin. Your investment $1,000.00
隔夜费用 -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
-0.024068%
空头隔夜费

Short position overnight fee

Margin. Your investment $1,000.00
隔夜费用 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
0.001846%
隔夜费时间 21:00 (UTC)
最小交易量 1
货币 USD
保证金 20%
上市交易所 United States of America
交易费 0%

*Information provided by Capital.com

关键数据
前收盘价* 33.91
开盘价* 33.99
1 年变化* -7.18%
日范围* 33.6 - 34.22
52 周范围 31.46-48.82
平均交易量（10 天） 1.10M
平均交易量（3 个月) 19.55M
市值 4.85B
市盈率 -100.00K
流通股 142.95M
收入 587.37M
EPS -1.90
股息（收益率 %） N/A
贝塔 0.54
下一个财报发布日期 May 2, 2023

所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date 平倉 Change Change (%) 開倉 High Low
Mar 24, 2023 33.91 0.61 1.83% 33.30 34.13 32.65
Mar 23, 2023 33.61 -1.58 -4.49% 35.19 35.41 33.28
Mar 22, 2023 35.16 0.14 0.40% 35.02 35.57 34.55
Mar 21, 2023 35.47 0.53 1.52% 34.94 35.75 34.67
Mar 20, 2023 35.45 -0.31 -0.87% 35.76 36.04 35.03
Mar 17, 2023 35.04 0.77 2.25% 34.27 35.20 33.70
Mar 16, 2023 34.86 1.50 4.50% 33.36 35.00 33.36
Mar 15, 2023 34.15 0.99 2.99% 33.16 34.18 32.63
Mar 14, 2023 33.74 0.43 1.29% 33.31 33.88 32.39
Mar 13, 2023 33.50 0.15 0.45% 33.35 34.65 33.35
Mar 10, 2023 33.91 0.05 0.15% 33.86 34.75 33.52
Mar 9, 2023 34.62 -0.80 -2.26% 35.42 35.72 34.28
Mar 8, 2023 35.62 0.12 0.34% 35.50 35.83 35.15
Mar 7, 2023 35.65 -0.22 -0.61% 35.87 36.14 35.49
Mar 6, 2023 36.12 -0.10 -0.28% 36.22 36.63 35.81
Mar 3, 2023 36.45 0.91 2.56% 35.54 36.71 35.01
Mar 2, 2023 35.66 0.39 1.11% 35.27 35.84 35.07
Mar 1, 2023 35.89 0.28 0.79% 35.61 36.31 34.93
Feb 28, 2023 35.71 0.62 1.77% 35.09 36.58 34.60
Feb 27, 2023 36.08 0.24 0.67% 35.84 36.38 34.90

Ionis Pharmaceuticals, Inc. Events

時間（協調世界時） (UTC) 國家 事件
No events scheduled
查看所有活動
  • 年度
  • 每季度
2022 2021 2020 2019 2018
总收入 587.367 810.456 729.264 1122.6 599.674
收入 587.367 810.456 729.264 1122.6 599.674
收入成本，共计 14.116 10.842 11.947 4.384 1.82
毛利 573.251 799.614 717.317 1118.21 597.854
总营业费用 997.558 849.269 901.346 822.912 661.046
销售/一般/行政费用，总计 150.295 170.947 332.222 286.644 244.622
研究与开发 833.147 634.953 526.877 465.688 414.604
异常费用（收入） 32.527 30.3 66.196 0
营业收入 -410.191 -38.813 -172.082 299.687 -61.372
利息收入（费用），非经营净值 9.876 10.798 37.592 39.765 -14.602
其他，净值 -7.274 -1.133 -0.062 -0.686 -0.182
税前净收入 -257.985 -29.148 -134.552 338.766 -76.156
税后净收入 -269.722 -28.597 -479.743 287.259 -117.115
少数股东权益 0 0 35.48 -9.116 58.756
未计算非常项目前的净收益 -269.722 -28.597 -444.263 278.143 -58.359
净收入 -269.722 -28.597 -444.263 278.143 273.741
普通股股东可获收益 (不含非经常性项目) -269.722 -28.597 -444.263 278.143 -58.359
普通股股东可获收益 (含非經常性項目) -269.722 -28.597 -444.263 278.143 273.741
摊薄调整 0
摊薄净收入 -269.722 -28.597 -444.263 278.143 273.741
摊薄后加权平均股 141.848 141.021 139.612 153.164 134.056
扣除特别项目的每股摊薄盈利 -1.90149 -0.20279 -3.18213 1.81598 -0.43533
每股正常摊薄盈利 -2.58703 -0.05286 -3.04106 2.18246 -0.43533
非常规项目总计 332.1
Gain (Loss) on Sale of Assets 149.604
Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
总收入 151.889 159.767 133.791 141.919 440.006
收入 151.889 159.767 133.791 141.919 440.006
收入成本，共计 3.686 1.515 4.745 4.17 2.226
毛利 148.203 158.252 129.046 137.749 437.78
总营业费用 359.908 218.921 219.305 199.423 219.401
销售/一般/行政费用，总计 47.95 34.416 33.802 34.127 37.6
研究与开发 308.272 182.99 180.758 161.126 179.575
营业收入 -208.019 -59.154 -85.514 -57.504 220.605
利息收入（费用），非经营净值 13.436 7.732 -5.064 -6.754 4.788
其他，净值 0.649 4.713 -12.297 0.187 -0.477
税前净收入 -44.33 -46.709 -102.875 -64.071 224.916
税后净收入 -52.43 -46.992 -105.135 -65.165 224.613
少数股东权益 0 0
未计算非常项目前的净收益 -52.43 -46.992 -105.135 -65.165 224.613
净收入 -52.43 -46.992 -105.135 -65.165 224.613
普通股股东可获收益 (不含非经常性项目) -52.43 -46.992 -105.135 -65.165 224.613
普通股股东可获收益 (含非經常性項目) -52.43 -46.992 -105.135 -65.165 224.613
摊薄净收入 -52.43 -46.992 -105.135 -65.165 224.613
摊薄后加权平均股 142.046 141.95 141.794 141.599 141.21
扣除特别项目的每股摊薄盈利 -0.36911 -0.33105 -0.74146 -0.46021 1.59063
Dividends per Share - Common Stock Primary Issue 0 0 0
每股正常摊薄盈利 -1.05369 -0.33105 -0.74146 -0.46021 1.59063
异常费用（收入） 0
Gain (Loss) on Sale of Assets 149.604
  • 年度
  • 每季度
2021 2020 2019 2018 2017
流动资产总额 2345.05 2130.71 2720.6 2207.89 1168.73
现金和短期投资 2114.97 1892.38 2499.54 2084.07 1022.72
现金等价物 869.191 397.664 683.287 278.82 129.63
短期投资 1245.78 1494.71 1816.26 1805.25 893.085
应收账款总额，净额 61.896 76.204 63.034 12.759 62.955
Accounts Receivable - Trade, Net 61.896 76.204 63.034 12.759 62.955
Total Inventory 24.806 21.965 18.18 8.582 9.982
Other Current Assets, Total 143.374 140.163 139.839 102.473 73.082
Total Assets 2611.69 2389.75 3233.11 2667.78 1322.77
Property/Plant/Equipment, Total - Net 196.069 181.077 166.251 132.16 121.907
Property/Plant/Equipment, Total - Gross 298.722 240.264 193.634 209.583
Accumulated Depreciation, Total -102.653 -74.013 -61.474 -87.676
Intangibles, Net 29.005 27.937 25.674 24.032 22.004
Other Long Term Assets, Total 41.567 50.034 320.59 303.706 10.129
Total Current Liabilities 240.55 598.898 273.005 280.294 243.612
Accounts Payable 11.904 17.199 16.067 28.66 24.886
Accrued Expenses 129.97 155.889 106.152 77.629 91.769
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.926 316.11 13.749 1.621
Other Current Liabilities, Total 97.75 109.7 150.786 160.256 125.336
Total Liabilities 1839.95 1646.47 1762.02 1619.7 1041.76
Total Long Term Debt 1228.02 623.529 770.3 632.971 605.856
Long Term Debt 1228.02 623.529 770.3 632.971 605.856
Capital Lease Obligations
Other Liabilities, Total 371.379 424.046 505.26 567.359 108.026
Total Equity 771.737 743.282 1471.09 1048.08 281.013
Common Stock 0.141 0.14 0.14 0.138 0.125
Additional Paid-In Capital 1964.17 1895.52 2203.78 2047.25 1553.68
Retained Earnings (Accumulated Deficit) -1159.9 -1131.31 -707.534 -967.293 -1241.03
Other Equity, Total -32.668 -21.071 -25.29 -32.016 -31.759
Total Liabilities & Shareholders’ Equity 2611.69 2389.75 3233.11 2667.78 1322.77
Total Common Shares Outstanding 141.21 140.366 140.34 137.929 124.976
Minority Interest 213.453 139.081 84.267
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
流动资产总额 2253.12 2345.05 2155.74 2238.42 1989.42
现金和短期投资 2052.39 2114.97 1987.1 2059.27 1819.99
现金等价物 542.513 869.191 632.953 565.119 414.155
短期投资 1509.88 1245.78 1354.15 1494.15 1405.84
应收账款总额，净额 26.122 61.896 9.068 24.004 23.397
Accounts Receivable - Trade, Net 26.122 61.896 9.068 24.004 23.397
Total Inventory 24.032 24.806 22.93 24.099 22.199
Other Current Assets, Total 150.577 143.374 136.643 131.045 123.827
Total Assets 2519.09 2611.69 2414.89 2497.07 2248.55
Property/Plant/Equipment, Total - Net 177.724 196.069 180.144 179.316 180.413
Intangibles, Net 29.295 29.005 30.038 29.373 28.795
Other Long Term Assets, Total 58.949 41.567 48.971 49.962 49.925
Total Current Liabilities 228.45 240.55 279.778 293.825 295.105
Accounts Payable 16.125 11.904 8.357 14.658 9.506
Accrued Expenses 115.781 129.97 108.001 105.372 108.029
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 4.206 0.926 65.045 69.848 69.504
Other Current Liabilities, Total 92.338 97.75 98.375 103.947 108.066
Total Liabilities 1809.52 1839.95 1884.36 1914.4 1567.99
Total Long Term Debt 1247.93 1228.02 1241.69 1240.7 870.916
Long Term Debt 1247.93 1228.02 1241.69 1240.7 870.916
Other Liabilities, Total 333.138 371.379 362.887 379.874 401.966
Total Equity 709.574 771.737 530.536 582.674 680.564
Common Stock 0.142 0.141 0.141 0.141 0.141
Additional Paid-In Capital 1983.08 1964.17 1942.35 1910.38 1925.8
Retained Earnings (Accumulated Deficit) -1225.07 -1159.9 -1384.52 -1302.05 -1221.18
Other Equity, Total -48.578 -32.668 -27.437 -25.796 -24.203
Total Liabilities & Shareholders’ Equity 2519.09 2611.69 2414.89 2497.07 2248.55
Total Common Shares Outstanding 141.753 141.21 141.184 141.022 140.924
  • 年度
  • 每季度
2021 2020 2019 2018 2017
净收入/起跑线 -28.597 -479.743 287.259 214.985 -10.783
经营活动产生的现金 30.799 35.892 345.627 602.906 174.149
经营活动产生的现金 15.487 13.365 12.54 10.706 6.708
Amortization 2.352 2.064 1.912 1.822 1.641
Deferred Taxes 0 341.729 0.911 -290.516 0
非现金物品 155.375 232.032 211.806 166.484 139.539
已付现金利息 4.778 6.247 9.87 9.592 8.035
营运资金的变化 -113.818 -73.555 -168.801 499.425 37.044
投资活动产生的现金 194.906 274.477 -41.274 -929.563 -358.291
资本支出 -11.955 -35.12 -30.905 -13.608 -34.764
其他投资现金流量项目，总计 206.861 309.597 -10.369 -915.955 -323.527
融资活动产生的现金 245.933 -596.609 100.021 475.865 229.087
融资现金流项目 -168.954 -558.097 -138.354 0 47.963
股票的发行（报废），净额 101.317 -38.512 141.375 475.865 205.106
债务的发行（退还），净额 313.57 0 97 0 -23.982
现金净变化 471.527 -285.623 404.467 149.19 44.945
Cash Taxes Paid 0.038 25.855 9.041 0
外汇效应 -0.111 0.617 0.093 -0.018
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -65.165 -28.597 -253.21 -170.744 -89.869
Cash From Operating Activities -31.65 30.799 -172.888 -117.314 -54.662
Cash From Operating Activities 3.701 15.487 11.665 7.951 3.917
Amortization 0.592 2.352 1.74 1.137 0.544
Deferred Taxes 0 0 0 0
Non-Cash Items 32.983 155.375 125.535 88.261 43.346
Cash Taxes Paid 0.002 0.038 0.003 0.002
Cash Interest Paid 0.594 4.778 3.527 2.866 0.594
Changes in Working Capital -3.761 -113.818 -58.618 -43.919 -12.6
Cash From Investing Activities -287.549 194.906 99.797 -22.174 78.856
Capital Expenditures -2.705 -11.955 -9.453 -6.13 -1.772
Other Investing Cash Flow Items, Total -284.844 206.861 109.25 -16.044 80.628
Cash From Financing Activities -7.325 245.933 308.423 306.965 -7.577
Financing Cash Flow Items -9.173 -168.954 -168.43 -167.966 -15.337
Issuance (Retirement) of Stock, Net 1.848 101.317 101.316 99.394 7.76
Foreign Exchange Effects -0.154 -0.111 -0.043 -0.022 -0.126
Net Change in Cash -326.678 471.527 235.289 167.455 16.491
Issuance (Retirement) of Debt, Net 313.57 375.537 375.537
投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
Fidelity Management & Research Company LLC Investment Advisor 14.9052 21307519 16360 2022-12-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.4574 13519789 736550 2022-12-31 LOW
T. Rowe Price Investment Management, Inc. Investment Advisor 8.1692 11678259 521564 2022-12-31 MED
Bellevue Asset Management AG Investment Advisor 6.8161 9743900 280500 2022-12-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.986 7127720 135266 2022-12-31 LOW
ClearBridge Investments, LLC Investment Advisor/Hedge Fund 3.7954 5425642 -348250 2022-12-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.9511 4218729 457774 2022-12-31 LOW
T. Rowe Price Associates, Inc. Investment Advisor 2.9049 4152607 -508999 2022-12-31 LOW
Tweedy, Browne Company LLC Investment Advisor 2.4771 3541136 818148 2022-12-31 LOW
ARK Investment Management LLC Investment Advisor 1.8702 2673538 -1039569 2022-12-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.408 2012723 111580 2022-12-31 LOW
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 1.3946 1993600 1224700 2022-12-31 LOW
Camber Capital Management LP Hedge Fund 1.3466 1925000 0 2022-12-31 MED
First Trust Advisors L.P. Investment Advisor 1.2458 1780933 -296327 2022-12-31 LOW
Macquarie Investment Management Investment Advisor 1.0435 1491687 657646 2022-12-31 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.907 1296647 465428 2022-12-31 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 0.8788 1256268 53922 2022-12-31 LOW
Deep Track Capital LP Hedge Fund 0.8435 1205773 1205773 2022-12-31 MED
Renaissance Technologies LLC Hedge Fund 0.8246 1178814 311100 2022-12-31 HIGH
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.7966 1138714 15634 2022-12-31 LOW

为什么选择 Capital.com？让我们的数字来说话。

Capital.com Group

500K+

交易者

92K+

每月活跃客户

$53M+

每月投资额

$30M+

每月提取金额

交易計算器

如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。

貿易佣金
0
  • 1:1
杠杆
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
投資
交易規模（槓桿 x 投資）：
開倉

平倉

做空 做多
過去的表現並不是未來結果的可靠指標
盈利/失利

Ionis Pharmaceuticals Company profile

关于 Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc.从事发现和开发核糖核酸（RNA）靶向治疗药物。 公司主要专注于我们的心血管和神经病学专营权。 其产品包括SPINRAZA、TEGSEDI和WAYLIVRA。 SPINRAZA用于治疗所有年龄段的脊髓性肌肉萎缩症（SMA）患者，这是一种进行性的、衰弱的、往往是致命的遗传性疾病。 TEGSEDI用于治疗由遗传性转甲状腺素（TTR）、淀粉样变（hATTR）引起的多发性神经病患者，这是一种衰弱的、进行性的和致命的疾病。 WAYLIVRA是一种反义药物，适用于成年患者的饮食辅助治疗。 公司有六种以上的药物处于III期研究中，涉及八个适应症，其中包括Eplontersen (TTR)、Olezarsen (ApoC-III)、Donidalorsen (PKK)、ION363 (FUS)、Pelacarsen (Apo(a)) 和Tofersen (SOD1)。 其正在开发的心血管药物包括Eplontersen、Olezarsen、Pelacarsen、ION449（PCSK9）、Fesomersen和IONIS-AGT-LRx。

Industry: Biotechnology & Medical Research (NEC)

2855 Gazelle Court
CARLSBAD
CALIFORNIA 92010
US

收入报表

  • Annual
  • Quarterly

人们也观看

Oil - Crude

72.91 Price
+5.260% 1D Chg, %
多头隔夜费 -0.0180%
空头隔夜费 -0.0039%
隔夜费时间 21:00 (UTC)
价差 0.03

BTC/USD

27,118.50 Price
-2.520% 1D Chg, %
多头隔夜费 -0.0616%
空头隔夜费 0.0137%
隔夜费时间 21:00 (UTC)
价差 60.00

XRP/USD

0.48 Price
+7.770% 1D Chg, %
多头隔夜费 -0.0753%
空头隔夜费 0.0069%
隔夜费时间 21:00 (UTC)
价差 0.00424

Gold

1,958.76 Price
-1.010% 1D Chg, %
多头隔夜费 -0.0180%
空头隔夜费 0.0097%
隔夜费时间 21:00 (UTC)
价差 0.30

还在找一位您可以信任的经纪商吗？

加入成为全球500,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易